F-Prime Capital

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Latchel, Inc. is a technology company that specializes in providing an online platform for maintenance coordination tailored for property managers and landlords. Founded in 2016 and based in Bellevue, Washington, Latchel offers tools to track maintenance requests and facilitate vendor selection. The platform aims to enhance operational efficiency by allowing residents to schedule maintenance and manage tasks, thereby improving response times and resident satisfaction. By streamlining maintenance processes, Latchel enables property management companies to increase their net margins while delivering better service to tenants.

Spry is a cloud-based operating system that allows movement health professionals to collect and analyze patient data in real time.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

Peptone Ltd develops and provides artificial intelligence (AI) solutions for addressing protein developability problems in biotechnology, biopharmaceutical, and life sciences industries. The company offers antibody designing and optimization, protein database, automated thermos-stability engineering, and hybrid AI deployment solutions. Additionally, it provides CassandraAI, a silico protein engineering platform. Peptone Ltd was founded in 2016 and is headquartered in London, United Kingdom.

Developer of a deep learning platform intended to deliver medicines of transformational efficacy for patients. the company platform delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies, enabling doctors in treating undruggable disease targets.

Teleo specializes in transforming existing heavy machinery into remote-controlled robots, allowing operators to control equipment from a significant distance. By retrofitting current fleets with its advanced supervised autonomy technology, Teleo enables operators to seamlessly switch between machines and job sites, enhancing both productivity and safety. The company's approach allows machine operators to work from remote operation centers rather than being confined to the equipment's cabin, ultimately improving operational efficiency and providing valuable insights into job site conditions.

Proof Diagnostics focuses on developing CRISPR-based molecular tests for the detection of COVID-19. The company aims to empower communities by providing rapid diagnostic kits that enable medical professionals to effectively test patients for coronavirus infections. By leveraging advanced genetic technologies, Proof Diagnostics contributes to improved health outcomes and better management of infectious diseases.

Doceree Inc operates a programmatic physician engagement and advertising platform that facilitates targeted advertising for healthcare professionals. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, the company provides access to exclusive physician-only platforms. Utilizing artificial intelligence, data segmentation, and analytics, Doceree enables advertisers to identify and reach healthcare professionals across various digital channels, including physician networking sites, medical journals, and telemedicine platforms. The company's services cater to a diverse clientele, including media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals, allowing them to deliver accurate and transparent messaging at scale.

Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.

AmplifyMD is a telemedicine platform connecting over 3,300 medical institutions with a lack of specialty access, often in rural or small regions to a network of leading specialists.AmplifyMD provides both the clinical team as well as the software to streamline and automate virtual care delivery and billing workflows and integrates seamlessly with hospitals' existing EHRs.

Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.

Mathison is the first all-inclusive diversity hiring platform. We centralize hundreds of diverse talent networks and uses AI to help employers source diverse candidates for their most important roles. Mathison’s platform offers a robust candidate marketplace, tools for diversity measurement, detecting job description bias and diversity raining courses for employees.

SKUteam founded in 2020: a transformational year for global businesses amidst a global pandemic, by a group of early former Flexport executives. Our vision is to democratize the production process in global manufacturing, starting with the apparel and home furnishing industries. SKUteam acts as your localised inspection agency, overseeing sample development and approvals, raw material inspections, in-line/top sample inspections and a final AQL inspection prior to ship out. SKUteam's unique platform will deliver an unprecedented level of visibility to take the guesswork out of the ever changing production process, ensuring brands can go to market fast, with confidence and the highest quality products.

Operator of an open marketplace enterprise platform intended to equip and enable payers to achieve accurate payments in the healthcare field. The company's platform offers a reference source repository, curated content, and payment accuracy technology, enabling users to reduce costs across the total cost for payment accuracy, find it easier to keep up with changes, and innovate new concepts.

Canary Technologies LLC is an enterprise hospitality technology company based in San Francisco, California, focused on modernizing hotel operations and enhancing guest experiences. The company develops application software that facilitates offline hotel bookings and includes features such as contactless check-in, digital authorizations, electronic signatures, and customizable amenity stores. Its platform aims to replace outdated systems in the hospitality sector, allowing hoteliers to improve efficiency, boost revenue, and reduce operational costs. Trusted by thousands of hotels worldwide, including some of the largest and most iconic brands, Canary Technologies leverages support from top investors in Silicon Valley to deliver innovative solutions that increase staff productivity, ensure compliance, and minimize fraud and chargebacks.

Expressable is an online speech therapy practice that addresses communication disorders for both children and adults. Founded in 2019 and headquartered in Austin, Texas, the company has developed a parent-focused care model that leverages technology and education to integrate speech therapy techniques into everyday life. The platform offers a range of services, including accent modification, aphasia, apraxia of speech, and support for autism spectrum disorder, among others. By providing weekly practice activities, Expressable aims to enhance speech and language outcomes, enabling individuals to improve their communication skills effectively.

Parrot Software specializes in developing comprehensive restaurant management solutions that integrate software and hardware to optimize operations for restaurants and fast-food establishments. Its platform encompasses essential functions such as point of sale, inventory management, customer payments, ordering, seating, and data visualization. By providing back-office tools that streamline these various tasks, Parrot Software enables clients to enhance the efficiency and effectiveness of their restaurant operations. The company's focus on innovation aims to deliver superior satisfaction in both service and operational management for its customers.

K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Notabene, Inc. is a New York-based company that specializes in developing a software as a service (SaaS) platform designed for crypto compliance in the financial industry. Founded in 2020, Notabene enables businesses to adhere to evolving global regulations for cryptocurrency transactions, particularly focusing on the Travel Rule. The company offers a unified API and dashboard that assists compliance officers in managing risks associated with both Travel Rule and non-custodial transactions. By simplifying compliance processes, Notabene enhances transaction confidence for its clients, facilitating increased interaction with a broad network of crypto businesses. This ultimately supports the growth of transaction volumes and fosters business expansion for its customers.

Hone Group Inc. is a company that develops and operates a platform for live online leadership and management training, primarily aimed at enhancing both hard and soft skills within organizations. Founded in 2017 and based in San Francisco, California, Hone provides a comprehensive development platform that facilitates the sourcing, management, and delivery of instructor-led training programs. The company's offerings include training in areas such as management, diversity and inclusion, communication, conflict management, team building, and interpersonal skills. Hone's platform is designed to support organizations of various sizes by measuring the impact of training and promoting behavior change, human connection, and continuous progress. Through its innovative approach, Hone aims to uplift human skills development in modern, distributed teams.

We believe everyone should have the opportunity to live their best lives and age with dignity. That’s why we’re reinventing primary care with an approach designed to profoundly improve the healthcare and aging experience for older adults and their loved ones.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Burro is a mobile application for Android and iOS devices that offers delivery and on-demand moving services to its users. The application enables its users to request pickups by filling up their personal information and items required. The platform offers its services to individuals and businesses. Its delivery portfolio consists of household goods, carpets, wood, and retail store items. Burro was launched in 2014 by Jason Ervin and Ethan Hurtado and is based in Texas.

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Zus Health is a developer of a healthcare data platform designed to enhance digital health by facilitating the creation of customized technologies and services. The platform connects both health and non-health information, offering a comprehensive view of patients while allowing for the sharing of clinical and non-clinical data without the need for shared applications. By removing traditional barriers in healthcare technology development, Zus Health empowers healthcare professionals to develop solutions that are more affordable and tailored to individual needs, ultimately aiming to improve the overall healthcare experience.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

AppliedVR, Inc. specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, specifically for managing pain and anxiety in various settings such as hospitals and surgery centers across the United States. Founded in 2013 and based in Los Angeles, the company has established partnerships with leading healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles. Its therapeutic virtual reality platform has been utilized by over 20,000 patients in more than 250 hospitals and in eight countries. The technology is designed to address both acute and chronic pain, as well as anxiety related to medical procedures, offering clinically validated, on-demand solutions. Inspired by extensive academic research, AppliedVR seeks to redefine pain management practices in clinical environments and at home, aiming to establish itself as a leading digital health solution provider in this field.

Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Atalanta Therapeutics is a biotechnology company focused on developing innovative treatment options for neurodegenerative diseases through its proprietary RNA interference platform. The company aims to create therapeutics that target various conditions, including Huntington's disease by specifically targeting the HTT gene. By addressing the underlying causes of these diseases, Atalanta Therapeutics seeks to provide clinicians with effective strategies to halt disease progression and improve patient outcomes.

ConnexPay LLC is a payment solution provider based in Bonita Springs, Florida, specializing in the travel and e-commerce markets. Established in 2017, the company offers an innovative platform that enables internet merchants to accept customer payments through the issuance of single-use virtual credit cards. This technology streamlines payment processes by minimizing risks, reducing acceptance costs, and eliminating the need for large merchant reserves or lines of credit. ConnexPay's integrated solution includes powerful anti-fraud detection and PCI-certified payment acceptance and issuance, all facilitated through their patent-pending intelligent routing system. By partnering with various financial institutions, ConnexPay allows clients to efficiently manage payments to suppliers while ensuring secure transactions for customer payments. This comprehensive approach simplifies financial operations for businesses acting as intermediaries in the travel and e-commerce sectors.

Argyle Systems Inc. develops an infrastructure-as-a-service platform that grants businesses access to workforce data. Its primary offering, Argyle, is a workforce platform that allows gig workers to authenticate their accounts, enabling their data to stream directly to businesses that provide products and services. The company focuses on maximizing the personal value of workers' data through a consumer-controlled software gateway to employment records. Additionally, Argyle offers a risk assessment service for contractors, along with financial visibility and recommendations. The company's services cater to insurance providers and credit card issuers. Founded in 2018, Argyle is headquartered in New York, New York.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.

Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to developing targeted therapies for rare disorders, particularly those associated with neurofibromatosis type 1 and related conditions. The company specializes in creating novel therapies aimed at addressing the needs of patients suffering from immunosuppressant-mediated squamous cell carcinoma and congenital birthmarks, including keratinocytic epidermal nevi and nevus sebaceous. NFlection focuses on first-in-class MEK inhibitors that target the aberrant activation of the Ras/Raf/MEK/ERK pathway, which is central to these disorders. Founded in 2014 and headquartered in Wayne, Pennsylvania, NFlection Therapeutics is committed to advancing treatments that can significantly impact the lives of patients with these challenging conditions.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

AvantStay is a hospitality brand specializing in short-term rentals tailored for group travel, primarily targeting millennial consumers. Founded in 2016 and headquartered in Los Angeles, California, the company leverages technology to offer affordable and authentic vacation experiences. AvantStay's platform facilitates a seamless booking process, allowing users to browse and reserve rental homes that meet their specific needs. By focusing on curated group experiences, AvantStay aims to redefine how people travel by enhancing the convenience and quality of short-term rental accommodations.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.

Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.

Owkin is an artificial intelligence company founded in 2016, with headquarters in New York and an additional office in Paris. The company focuses on developing machine learning software for medical research, enabling researchers to test AI models on distributed data. Owkin's offerings include Owkin Lab, which facilitates data connectivity by therapeutic area; Owkin Loop, which provides validated and packaged models; and a comprehensive software stack for full-stack services. The company currently has 30 live models and an additional 40 in development. Owkin aims to empower medical researchers in hospitals, universities, and pharmaceutical companies to better understand variations in drug efficacy among patients, enhance the drug development process, and identify optimal treatments for individual patients, ultimately improving treatment outcomes. The company is supported by various investors and has a scientific board to guide its research initiatives.

TreeENT Health, established in 2017 and based in Hangzhou, China, operates as a specialized surgical center focusing on ear, nose, and throat (ENT) conditions. The company, also known as Renshu Medical, provides a comprehensive range of services for various ENT diseases, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. Utilizing advanced technology, TreeENT offers minimally invasive surgical procedures, as well as diagnostic services such as Danish ear hearing detection, nasal endoscopy, and nasopharyngoscopy. Additionally, the company facilitates patient access through WeChat for appointment scheduling with medical experts. With a commitment to high-quality care, TreeENT aims to deliver professional medical services that align with international standards and support personalized chronic disease rehabilitation.

Castle provides advanced fraud detection and prevention solutions tailored for online businesses of all sizes. By offering technology that was once exclusive to banks and large financial institutions, Castle enables various customer-facing applications—including e-commerce platforms, mobile apps, and cryptocurrency services—to safeguard user accounts against unauthorized access. The company's APIs facilitate account hijack protection by monitoring user behavior through device fingerprinting, keystroke analysis, browsing history, and numerous other indicators. In the event of suspicious activity, both administrators and account owners receive immediate alerts, empowering them to respond swiftly and effectively to potential threats.

Castle manages rental homes for landlords using automation and on-demand labor. It finds tenants, collect rent, and coordinate maintenance, allowing owners to kick back, relax, and never worry about their rental properties again. Owners either have to deal with this whole mess themselves, or spend 10% of their rental income on a traditional property management company that requires constant supervision and is often incentivized to act against the owner’s best interest. There are 43 million rental units in the United States, and most of them are currently managed with some combination of faxes, mail, and unreturned voicemails on the landlord’s personal phone. Castle moves all of property management into a seamless online experience, providing owners with transparency, speed, and incredible customer service—plus huge cost savings over traditional management. Renters get great service and instant updates about important issues.

Innovusion, Inc. is a prominent developer of image grade LiDAR sensor systems, specifically designed for level 4 and 5 autonomous vehicles and advanced driver-assistance systems (ADAS). Founded in 2016 and based in Sunnyvale, California, Innovusion focuses on providing solutions that combine range, resolution, and hardware-accelerated sensor fusion within a compact and cost-effective framework. This unique approach makes their products suitable for the most demanding applications in the autonomous driving sector. As a venture-backed company, Innovusion is positioned at the forefront of innovation in the rapidly evolving automotive technology landscape.

Nebula Genomics, founded in 2016 and based in San Francisco, California, is a company focused on human genome sequencing and health data. It aims to create a comprehensive and trusted marketplace for genomic and health data, facilitating access for consumers, researchers, and the medical community. Utilizing blockchain technology, Nebula Genomics empowers individuals to control their genomic data while receiving compensation for its use. The marketplace aggregates extensive genetic information, which researchers can analyze to enhance drug development and streamline clinical trials, ultimately contributing to personalized medicine. The company's innovative DNA sequencing technology allows for the examination of all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, enabling clients to explore genetic variants comprehensively. Nebula Genomics was co-founded by Harvard genomics pioneer George Church and has received backing from notable investors.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with significant unmet medical needs. The company, based in Oakland, California, was incorporated in 2016 and is a subsidiary of Zogenix, Inc. Modis Therapeutics is advancing its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapeutic candidate is specifically designed to address thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance, increasing mitochondrial DNA copy number, and enhancing cell function, Modis Therapeutics aims to provide meaningful treatment options that can prolong the lives of affected patients.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.

Notable is an AI-powered healthcare startup focused on enhancing physician-patient interactions by automating and digitizing the recording of medical visits. The company's platform utilizes natural language processing and voice recognition technology to automatically capture and structure conversations between doctors and patients, facilitating the seamless update of electronic health records. Additionally, Notable's system recommends appropriate billing codes, streamlining administrative tasks for healthcare providers. By improving the efficiency of these interactions, Notable aims to allow physicians to dedicate more time to patient care rather than paperwork.

AvantStay is a hospitality brand specializing in short-term rentals tailored for group travel, primarily targeting millennial consumers. Founded in 2016 and headquartered in Los Angeles, California, the company leverages technology to offer affordable and authentic vacation experiences. AvantStay's platform facilitates a seamless booking process, allowing users to browse and reserve rental homes that meet their specific needs. By focusing on curated group experiences, AvantStay aims to redefine how people travel by enhancing the convenience and quality of short-term rental accommodations.

Metcela Inc. specializes in developing fibroblast-based therapies for cardiac diseases, focusing on regenerative medicine for conditions such as Ischemic Heart Disease. Founded in 2016 and based in Kawasaki-shi, Japan, the company utilizes VCAM-1-positive cardiac fibroblasts derived from patients' own cells. This innovative approach aims to replenish and restore damaged cardiac muscle and its surrounding microenvironment, enhancing the heart's natural healing capabilities. By repairing rather than replacing damaged cells, Metcela seeks to provide effective and cost-efficient treatments for heart failure, offering new hope for patients suffering from cardiac ailments.

Founded in 2015, Even Financial is an NYC based fintech company focused on evolving how financial institutions connect with consumers and provide them the best product recommendations at the right moment, facilitating an on-demand and personalized customer acquisition experience across the entire financial services ecosystem. The Even platform serves as a trusted intermediary for financial institutions - including Prosper, Lending Club, and Marcus by Goldman Sachs - that helps find consumers and distribute their products digitally. Even’s industry-leading search, comparison, and recommendation API is an infrastructure layer that enables hundreds of diverse partners - including Credit.com, Transunion, Money Under 30, Credit Sesame, and The Penny Hoarder - to power comprehensive personal finance websites, mobile apps, and other offerings with a modern platform that is proven to accelerate customer acquisition through optimal product recommendations, lowering cost of acquisition and maximizing monetization. Even Financial is based in New York.

CareStack is a cloud-based platform designed to meet the comprehensive administrative and clinical needs of dental practices. It integrates various functionalities, including practice management, patient engagement, scheduling, telehealth conferencing, charting, automated reminders, claims processing, and business analytics, all within a single interface. This all-in-one solution is particularly beneficial for large and growing dental practices, helping them enhance productivity, reduce operational costs, and improve patient care. By centralizing and automating key processes, CareStack aims to elevate the financial success of dental offices while ensuring a streamlined experience for both patients and staff.

Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

Zenflow, Inc. is a medical device company based in San Francisco, California, founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists. The company focuses on developing and marketing a spring device designed to provide relief for permanent benign prostatic hyperplasia (BPH) symptoms in men. Zenflow's product addresses urinary obstruction without damaging surrounding tissues, offering a novel solution for patients and healthcare providers. The founders were motivated by the frustrations experienced by patients with existing treatment options, aiming to fulfill a significant unmet clinical need in urology.

Lighthouse, operating under the name OTA Insight Ltd, specializes in providing cloud-based business intelligence solutions for the hospitality industry. Founded in 2012 and based in London, the company offers a suite of tools including Rate Insight, Parity Insight, and Revenue Insight, which help hoteliers make informed revenue and distribution decisions. These solutions utilize advanced data systems and forecasting algorithms to deliver real-time market demand forecasts, rate intelligence, and ranking analytics. With a strong emphasis on customer support, OTA Insight’s platform integrates seamlessly with various hotel management systems and data providers, supporting over 50,000 properties in 168 countries. Recognized as a leader in hospitality business intelligence, the company has garnered accolades and continues to empower hoteliers to optimize occupancy rates and enhance profitability.

Oviva is a digital health company providing medically-oriented nutritional counseling services in Switzerland, Germany, and the United Kingdom. Founded in 2013 and headquartered in Ingenbohl, Switzerland, Oviva offers personalized behavior change programs aimed at managing diet and lifestyle-related health issues like obesity and diabetes. Their services are delivered through a network of qualified dietitians who work with clients both in clinics and remotely. The company has developed a smartphone application that allows users to engage with their dietitian, maintain a food diary, set health goals, and access tailored educational materials. This technology-enabled approach helps patients achieve better health outcomes while reducing the need for in-person appointments, ultimately lowering healthcare costs by preventing complications associated with these conditions.

Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Vestwell is a digital retirement platform founded in 2016 and headquartered in New York, New York. It simplifies the offering and administration of 401(k) plans for advisors, employers, and employees by eliminating traditional challenges associated with retirement plan management. The platform features seamless plan design, automated onboarding, and streamlined administration, all while providing flexible investment strategies at competitive prices. By serving as a single point of contact, Vestwell enhances the retirement planning experience, ensuring that both plan sponsors and participants have their interests prioritized. Additionally, the platform supports registered investment advisors with automated compliance options tailored to the specific rules and regulations governing defined contributions.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

RiskRecon is the only continuous vendor monitoring solution that delivers risk-prioritized action plans custom-tuned to match your risk priorities, providing the world’s easiest path to understanding and acting on third-party cyber risk. Partner with RiskRecon to build your scalable, third-party risk management program to realize dramatically better risk outcomes. To learn more about RiskRecon’s approach, request a demo or visit the website at www.riskrecon.com.

Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.

Blispay Inc. is a financial technology company based in Baltimore, Maryland, that specializes in providing mobile payment solutions and point-of-sale financing for small and midsize retailers. Founded in 2014, Blispay offers a mobile-centric credit card that allows merchants to provide financing options to their customers without the need for technical integration or financial obligations. The Blispay Visa Card features instant issuance, six months of special financing, and a cash-back incentive, making it an attractive option for both retailers and consumers. The company's founding team includes industry veterans with backgrounds from notable organizations, enhancing its capability to deliver innovative financial products that meet the needs of modern shoppers and merchants alike.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Whatfix is a digital adoption platform that assists enterprises in enhancing their training and support initiatives by delivering contextual information in a user-friendly manner. The platform employs real-time interactive guidance technology to provide personalized, in-app user assistance, transforming traditional training and support methods. By offering just-in-time guidance, Whatfix enables users to complete tasks more efficiently across various applications, including web, desktop, and mobile. This approach fosters a unified digital workflow and self-help experience, leading to increased user adoption and productivity. Clients benefit from improved process compliance, reduced time for completing critical operations, and access to data-driven insights that support informed decision-making.

WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Axoni is a New York-based technology firm focused on capital markets, specializing in distributed ledger solutions. Founded in 2013 by experts in distributed ledger technology and cryptography, Axoni serves major financial institutions and capital markets service providers. The company's offerings include the deployment of distributed ledger technology, custom smart contract development, and advanced analytics tools. Their software integrates traditional financial technologies with blockchain capabilities, providing market information and in-depth trend analysis. This comprehensive approach enables investment funders, exchange operators, and professional traders to enhance their systems for managing legal records, lifecycle events, and cash flow calculations.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Codeship Inc. is a provider of hosted continuous integration solutions that specialize in automating the build, testing, and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, the company aims to streamline development cycles for software companies, thereby reducing the risk of bugs and fostering innovation. By managing the testing and release processes, Codeship allows developers to focus on creating better products more quickly. In January 2013, the company changed its name from Railsonfire Limited and, as of February 2018, operates as a subsidiary of CloudBees, Inc.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.

Haiui Health Technology is a mobile platform for hospitals to connect patients, optimise hospital visits and streamline admin workflow.

PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.

Medwell Ventures Private Limited is a provider of specialty home healthcare services in India, focusing on a range of therapeutic areas. Established in 2014 and headquartered in Bengaluru, the company offers a variety of wellness and care programs, including preventive screening, palliative care, and bedside nursing. Its services encompass 24×7 medical support, physician consultations, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, and pharmacy support. By integrating different healthcare delivery channels, Medwell Ventures aims to enhance the accessibility and personalization of medical treatment for patients with chronic diseases and diverse health profiles.

VitalWare, LLC is a provider of cloud-based revenue cycle software solutions tailored for healthcare organizations. Established in 2011 and based in Yakima, Washington, the company offers a range of products designed to improve the efficiency and accuracy of healthcare documentation, coding, billing, and auditing processes. Key offerings include VitalCDM, which facilitates charge management and workflow customization; VitalCDI, a clinical documentation improvement tool; and VitalAuditor, an audit platform for data analysis. Additionally, VitalWare provides solutions for charge integrity, price transparency compliance, and advanced coding resources, all aimed at enhancing the revenue cycle for healthcare providers. With a client base exceeding 590 institutions, VitalWare also offers consulting services to assist providers in optimizing their processes and ensuring appropriate reimbursement.

Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.

Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.

Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly bacterial vaginosis (BV). Founded in 2012, the company is based in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut. Its lead product, Solosec (secnidazole), is a novel 5-nitroimidazole antibiotic designed for a one-time oral treatment of bacterial vaginosis, addressing a significant unmet need in women's healthcare. Symbiomix operates as a subsidiary of Lupin Inc. and is supported by prominent healthcare venture capital firms. The company aims to provide effective therapeutic options for gynecologic infections that have been historically overlooked.